Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders

Ahmed Karam Farag, Ahmed Elkamhawy, Ashwini M. Londhe, Kyung Tae Lee, Ae Nim Pae, Eun Joo Roh

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Tyrosine kinases including LCK and FMS are involved in inflammatory disorders as well as many types of cancer. Our team has designed and synthesized thirty novel pyrimidine based inhibitors targeting LCK, classified into four different series (amides, ureas, imines (Schiff base) and benzylamines). Twelve of them showed nanomolar IC50 values. Compound 7g showed excellent selectivity profile and was selectively potent over FMS kinase (IC50 value of 4.6 nM). Molecular docking study was performed to help us rationalize the obtained results and predict the possible binding mode for our compounds in both LCK and FMS. Based on the obtained biological assay data and modelling results, a detailed SAR study was discussed. As a further testing regarding the anti-inflammatory effect of the new compounds, in vitro cellular assay over RAW 264.7 macrophages was performed. Compound 7g exhibited excellent anti-inflammatory effect. Therefore, we report the design of novel phenoxypyrimidine derivatives as potent and selective LCK inhibitors and the discovery of 7g as potent and selective FMS/LCK dual inhibitor for the potential application in inflammatory disorders including rheumatoid arthritis (RA).

Original languageEnglish
Pages (from-to)657-675
Number of pages19
JournalEuropean Journal of Medicinal Chemistry
Volume141
DOIs
StatePublished - 1 Dec 2017

Keywords

  • FMS
  • Inflammation
  • LCK
  • Molecular docking and RAW 264.7 macrophages
  • Synthesis

Fingerprint

Dive into the research topics of 'Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders'. Together they form a unique fingerprint.

Cite this